The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer - Centre de recherche des Cordeliers Access content directly
Journal Articles Cancers Year : 2023

The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer

Ana Regina de Abreu
Ken Op de Beeck
Pierre Laurent-Puig
Valerie Taly
Leonor Benhaim
  • Function : Author
  • PersonId : 1313794

Abstract

Currently, methods including endoscopy, radiology, and carcinoembryonic antigen levels allow for the detection of colorectal cancer (CRC) at an early stage and the ability to follow the evolution of the disease during treatment. However, these are not always sensitive and specific enough for timely intervention. This leads, amongst other consequences, to delays in treatment or even to overtreatment. Circulating tumor DNA (ctDNA) has shown promise in filling this gap, allowing treatment to be personalized at each stage of the disease and, thus, tailored to each patient's needs. This review article focuses on the current clinical use and future direction of ctDNA for CRC management.
Fichier principal
Vignette du fichier
cancers-15-01284.pdf (949.11 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-04301271 , version 1 (22-11-2023)

Identifiers

Cite

Ana Regina de Abreu, Ken Op de Beeck, Pierre Laurent-Puig, Valerie Taly, Leonor Benhaim. The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer. Cancers, 2023, 15, ⟨10.3390/cancers15041284⟩. ⟨hal-04301271⟩
6 View
9 Download

Altmetric

Share

Gmail Facebook X LinkedIn More